Drug Trial Radar · NCT07129252
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 26, 2025
Primary completion
Aug 2027
Study completion Aug 2029
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Conditions
- SST2-positive Neuroendocrine Neoplasms
- Neuroendocrine Tumors
- Neuroendocrine Neoplasm
Interventions
CRN09682Drug
Study drug CRN09682 intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Dose Escalation) Incidence and severity of DLTs.Time frame: From first dose through Day 21.
- (Dose Escalation) Incidence and severity of AEs and SAEs at each dose level and incidence of AEs leading to discontinuation from study drug.Time frame: From first dose of study drug to 30 days after the last dose.
- (Dose Expansion) Nature, incidence, and severity of AEs and SAEs at the Expansion Dose.Time frame: From first dose of study drug to 30 days after the last dose.
- (Dose Expansion) Interruptions at the Expansion Dose.Time frame: At Day 1 of each cycle through study completion, approximately 2 years.
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Phoenix, Arizona
Crinetics Study Site
Duarte, California
Crinetics Study Site
Newport Beach, California
Crinetics Study Site
Orange, California
Crinetics Study Site
San Francisco, California
Crinetics Study Site
Aurora, Colorado
Crinetics Study Site
Denver, Colorado
Crinetics Study Site
New Haven, Connecticut
Crinetics Study Site
Atlanta, Georgia
Crinetics Study Site
Lexington, Kentucky
Crinetics Study Site
Metairie, Louisiana
Crinetics Study Site
Detroit, Michigan
Crinetics Study Site
Grand Rapids, Michigan
Crinetics Study Site
Rochester, Minnesota
Crinetics Study Site
New York, New York
Crinetics Study Site
Philadelphia, Pennsylvania
Crinetics Study Site
Philadelphia, Pennsylvania
Crinetics Study Site
Austin, Texas
Crinetics Study Site
Houston, Texas
Crinetics Study Site
Irving, Texas
Crinetics Study Site
Salt Lake City, Utah
Crinetics Study Site
Charlottesville, Virginia
Crinetics Study Site
Fairfax, Virginia
Crinetics Study Site
Barcelona, Spain
Crinetics Study Site
Barcelona, Spain
Crinetics Study Site
Madrid, Spain
Crinetics Study Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.